First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer

Varol, Umut; Dirican, Ahmet; Yildiz, Ibrahim; Oktay, Esin; Degirmenci, Mustafa; Alacacioglu, Ahmet; Barutca, Sabri; Karabulut, Bulent; Uslu, Ruchan

추천

검색

자료유형: 학술저널

저자정보: Varol, Umut (Katip Celebi University Ataturk, Izmir Tepecik Training and Research Hospital) Dirican, Ahmet (Katip Celebi University Ataturk, Izmir Tepecik Training and Research Hospital) Yildiz, Ibrahim (Katip Celebi University Ataturk, Izmir Tepecik Training and Research Hospital) Oktay, Esin (Adnan Menderes University Faculty of Medicine) Degirmenci, Mustafa (Medical Oncology Clinic, Izmir Tepecik Training and Research Hospital) Alacacioglu, Ahmet (Katip Celebi University Ataturk, Izmir Tepecik Training and Research Hospital) Barutca, Sabri (Adnan Menderes University Faculty of Medicine) Karabulut, Bulent (Department of Internal Medicine, Division of Medical Oncology, Ege University Faculty of Medicine) Uslu, Ruchan (Department of Internal Medicine, Division of Medical Oncology, Ege University Faculty of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제7호

발행연도: 2014.1

수록면: 3,157 - 3,161 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Unlike for fit elderly metastatic colorectal cancer (mCRC) patients, general approaches to initial treatment for the frail older mCRC patients are not clear. Our aim was to evaluate the efficiency and safety of first-line single-agent treatment in one such group. Materials and Methods: We retrospectively evaluated mCRC patients aged 70 or older with an Eastern Cooperative Oncology Group performance score of 2. They had no prior treatment and underwent first-line single-agent capecitabine or other monotherapies until disease progression or unacceptable toxicity. Results: Thirty-six patients were included. Most (n:28, 77.8%) were treated with capecitabine. One patient achieved a complete response and 5 patients had a partial response for an overall response rate of 16.6%. Twelve patients (33.3%) remained stable. Median progression free survival was 5 months (confidence interval (CI), %; 3.59-6.40) and median overall survival was 10 months (95 CI%; 8.1-11.8). Grade 3-4 toxicity was found in 6 patients (16.6%). Febrile neutropenia was not observed and there were no toxicity-associated deaths. Conclusions: Capecitabine is a safe chemotherapeutic agent with moderate activity for first-line treatment of older metastatic colorectal cancer patients with limited performance status.

#Capecitabine #monotherapy #elderly #colorectal cancer #metastasis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Varol, Umut

소속기관 Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital